Las células madre hematopoyéticas transducidas con lentivector para el reemplazo del gen UBE3A muestran un rescate completo de los síntomas de AS en el mo
Bienvenido a Neuren Pharmaceuticals (www.neurenpharma.com; ASX: NEU). Neuren es una empresa con sede en Melbourne que esta a la vanguardia de los esfuerzos p
15 February 2021 Ensayo exitoso de fase 1 para el NNZ-2591 de Neuren Después de un año de montaña rusa, un medicamento de Angelman se acerca a los pacient
EXQUISITE SCIENCE15 de Febrero, 2021 Mary Parker Después de un año de montaña rusa, un medicamento de Angelman se acerca a los pacientes Este año trajo d
By Allyson Berent, DVM, DACVIM At the annual Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December, Jodi Cook, Ph.D., Chief Operat
“Of all the childhood genetic neurologic disorders of the brain, Angelman syndrome may be the single best candidate for developing a definitive treatment (
Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to annou
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Flo
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome
Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES)
